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OBJECTIVES We sought to determine the role of conventional atherosclerosis risk factors in the
development and progression of transplant coronary artery disease (CAD) using serial
intravascular ultrasound imaging.
BACKGROUND Transplant artery disease is a combination of allograft vasculopathy and donor atherosclerosis.
The clinical determinants for each of these disease processes are not well characterized.
Intravascular ultrasound imaging is the most sensitive tool to serially study these processes.
METHODS Baseline intravascular ultrasound imaging was performed 0.9 6 0.5 months after transplan-
tation to identify donor atherosclerosis. Follow-up imaging was performed at 1.0 6 0.07 year
to evaluate progression of donor atherosclerosis and development of transplant vasculopathy.
Conventional risk factors for CAD included recipient age, gender, smoking history, diabetes
mellitus, hypertension and hypercholesterolemia.
RESULTS Donor-transmitted atherosclerosis was present in 36 patients (39%). At follow-up, progres-
sion of donor lesions was seen in 15 patients (42%) and 42 patients (45%) developed
transplant vasculopathy, leaving 35 patients (38%) without any disease. There was no
difference in any conventional risk factors in patients with and without allograft vasculopathy.
However, the severity of allograft vasculopathy was associated with a larger increase in low
density lipoprotein (LDL) cholesterol from baseline (p 5 0.02). High one-year post-
transplant serum triglyceride level and pretransplant body mass index were the only significant
predictors (p 5 0.03) for progression of donor atherosclerosis.
CONCLUSIONS Conventional atherosclerosis risk factors do not predict development of allograft vasculopa-
thy, but greater change in serum LDL cholesterol level during the first year after transplant
is associated with more severe vasculopathy. Therefore, maintenance of LDL cholesterol as
close to pretransplant values as possible may help to limit the rate of progression of acquired
allograft vasculopathy. (J Am Coll Cardiol 2001;38:206–13) © 2001 by the American
College of Cardiology
Transplant coronary artery disease (CAD) is the major
factor limiting the long-term success of cardiac transplan-
tation (1,2). Previous intravascular ultrasound (IVUS) stud-
ies have demonstrated that CAD in transplant patients
represents a combination of donor-transmitted atheroscle-
rosis and acquired allograft vasculopathy (3,4). Although
donor-transmitted atherosclerosis is common, the natural
history of this disease in the years following transplantation
remains unknown. Furthermore, the interaction between
the progression of donor atherosclerosis and development of
acquired allograft vasculopathy is not well characterized. No
studies have separately described the clinical factors that
determine the rate of progression for each of the sources of
this disease.
Necropsy studies cannot separate the two components of
transplant coronary disease, because the morphology of
end-stage lesions produced by the two processes is indistin-
guishable. However, IVUS, if performed shortly following
transplantation, enables precise identification and quantifi-
cation of atherosclerotic plaques present within the donor
heart. In 1992, we began imaging every patient undergoing
cardiac transplantation within two months following the
procedure and annually thereafter. In this study, we report
the natural history of the two components of transplant
coronary disease and the role of both conventional athero-
sclerotic risk factors and immunologic determinants on the
disease process.
METHODS
Patient population. The study cohort included all patients
who underwent orthotopic cardiac transplantation between
December 1992 and October 1995. Patients who were not
eligible for cardiac catheterization, who died during hospi-
talization or who could not provide informed consent were
excluded. Baseline angiography and IVUS examination was
performed within one month following transplantation, but
could be extended to two months if the patient was not
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clinically stable. Repeat angiography and intravascular ex-
amination were performed at one year.
Study variables. At the time of enrollment and at the
one-year anniversary, an investigator unaware of the IVUS
findings assessed both immunologic and conventional CAD
risk factors. Atherosclerosis risk factors included recipient
and donor age, gender, body mass index (BMI), smoking
history, diabetes mellitus, hypertension and presence of lipid
abnormalities. Pretransplant severe CAD was also consid-
ered a risk factor in this analysis. Immunologic determinants
included number of treated rejection episodes, mismatch in
human leukocyte antigen (HLA), blood type and/or gender.
The relationship of corticosteroids and cyclosporine dosage
to the changes in lipid values was also evaluated. This
analysis was performed utilizing an average of 3-, 6-, 9- and
12-month dose of these medications.
IVUS imaging. The method of IVUS imaging has been
previously reported in detail (3,4). Ultrasound images were
independently analyzed by technicians in the IVUS core
laboratory. Baseline and follow-up ultrasound tapes were
reviewed side by side using two identical video monitors.
This simultaneous evaluation allowed accurate matching of
pullback sequences. Angiographic and IVUS landmarks
such as side branches, pericardium and cardiac veins were
identified to assist site matching.
At each site selected for measurement, the analysis
operator measured the minimum and maximum intimal
thickness. The boundaries of the lumen and external elastic
membrane (EEM) were manually measured by planimeter
for direct measurements of cross sectional area and circum-
ference. From these tracings of the lumen and EEM
borders, the minimum and maximum diameter were also
determined. The disease burden was also assessed by com-
puting the percent of EEM cross-sectional area occupied by
atheroma defined as:
EEM area 2 lumen area
EEM area
3 100
All ultrasound measurements were performed from leading
edge to leading edge in the fashion customary for all
quantitative ultrasound techniques. Within each segment,
defined according to Coronary Artery Surgery Study
(CASS) classification (5), the operator identified two sites,
one with the least intimal thickness and another with the
greatest intimal thickness. In cases where the entire segment
was normal, one or two of the normal sites were randomly
selected for measurement.
Definitions. All coronary lesions were defined as a contig-
uous region of the coronary artery with a maximum intimal
thickness $0.5 mm with no intervening nondiseased sites.
If a diffusely diseased CASS segment was interrupted by a
nondiseased site, the segment was classified as containing
more than one lesion. If no intervening normal site was
present, the CASS segment was classified as containing a
single lesion. A donor lesion was defined as a site with
intimal thickness $0.5 mm at baseline examination. Ac-
quired allograft vasculopathy lesions were defined as sites
with intimal thickness $0.5 mm at one-year examination
where intimal thickness was ,0.5 mm at baseline exami-
nation. Progression of a donor lesion was defined as
.0.3 mm increase in intimal thickness at one-year
follow-up at a site that was abnormal at baseline examina-
tion.
Study subgroups. For analysis, the study cohort was sub-
divided into patient groups based upon the findings at
baseline and one-year examination. Patients with donor-
transmitted disease were subdivided into groups with and
without progression of donor atherosclerosis. An additional
subgroup consisted of patients with and without allograft
vasculopathy lesions at one-year examination. Patients with
allograft vasculopathy were subdivided into those with
relatively mild and more severe disease based upon the
percent area stenosis as defined previously. Because the
median area stenosis was 29% for all the vasculopathy
lesions, we divided the cohort into patient subgroups with
.29% and #29% area stenosis.
Statistical analysis. Normally distributed data are reported
as mean plus or minus one standard deviation. Chi-squared
or Fisher exact test was used to find significant association
between categorical variables. The Student t test was used to
compare mean values for continuous variables. Logistic
regression was used to determine the significant risk factors.
Multivariate analysis was done using stepwise logistic re-
gression, with variable entry and removal p values of 0.10
and 0.15, respectively. A p value of #0.05 was considered
significant. Univariate logistic regression was performed
using the variables listed in Table 1 for the subgroups with
and without allograft vasculopathy. A similar analysis was
performed for subgroups classified according to the severity
of disease for the variables listed in Tables 2 and 3. To
convert continuous variables to binary variables, sub-
groups were defined using conventional cutoffs employed in
epidemiological studies. These cutoffs included a total
cholesterol of .200 mg/dl, low density lipoprotein (LDL)
.160 mg/dl, high density lipoprotein (HDL) ,35 mg/dl,
triglycerides .200 mg/dl, a body mass index of .25 kg/m2,
recipient age .60 years, and donor age .35 years. Power of
the study was calculated to be 80% to detect differences in
cholesterol levels of 15%, 20% and 25% from baseline levels,
between patients with and without de novo lesions, with
Abbreviations and Acronyms
BMI 5 body mass index
CAD 5 coronary artery disease
CASS 5 Coronary Artery Surgery Study
EEM 5 external elastic membrane
HDL 5 high density lipoprotein
HLA 5 human leukocyte antigen
IVUS 5 intravascular ultrasound
LDL 5 low density lipoprotein
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Table 1. Conventional Atherosclerosis Risk Factors in Patients With and Without De Novo
Lesions of Transplant Vasculopathy
Characteristics
De Novo Disease
p Value
Absent
(n 5 51)
Present
(n 5 42)
Recipient age (yr) 49.7 6 10.3 52.3 6 11.4 ns
Gender (male %) 74 78 ns
Hypertension (%) 18 7 ns
Diabetes mellitus (%) 10 19 ns
Smoking history (%) 75 66 ns
History of ischemic cardiomyopathy (%) 59 48 ns
BMI (kg/m2)
At the time of transplant 25.2 6 4.9 25.3 6 4.8 ns
At 1-yr follow-up 28.3 6 5.4 27.9 6 6.7 ns
Pretransplant lipids
Total cholesterol (mg/dl) 183 6 51 163 6 46 ns
LDL (mg/dl) 123 6 42 112 6 41 ns
HDL (mg/dl) 34 6 13 29 6 10 ns
Triglycerides (mg/dl) 130 6 60 121 6 88 ns
Post-transplant lipids
Total cholesterol (mg/dl) 249 6 59 243 6 60 ns
LDL (mg/dl) 161 6 51 158 6 52 ns
HDL (mg/dl) 46 6 15 41 6 13 ns
Triglycerides (mg/dl) 205 6 120 229 6 126 ns
BMI 5 body mass index; HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; ns 5 not significant.
Table 2. Conventional Atherosclerosis Risk Factors in Patients With De Novo Lesion Stenosis
of #29% and .29%
Characteristics
Mean Luminal Stenosis
p Value
<29%
(n 5 21)
>29%
(n 5 21)
Recipient age (yr) 52.3 6 12.0 52.2 6 11.0 ns
Gender (male %) 81 76 ns
Hypertension (%) 19 5 ns
Diabetes mellitus (%) 19 19 ns
Smoking history (%) 62 70 ns
History of ischemic cardiomyopathy (%) 48 48 ns
BMI (kg/m2)
At the time of transplant 24.7 6 4.8 25.8 6 4.7 ns
At 1 yr follow-up 27.2 6 6.3 28.5 6 7.2 ns
Change in the first year 3.0 6 3.1 2.8 6 4.1 ns
Pretransplant lipids
Total cholesterol (mg/dl) 184 6 40 150 6 51 0.06
LDL (mg/dl) 128 6 39 102 6 31 0.06
HDL (mg/dl) 33 6 9 27 6 10 0.09
Triglycerides (mg/dl) 143 6 120 106 6 57 ns
Post-transplant lipids
Total cholesterol (mg/dl) 242 6 70 244 6 52 ns
LDL (mg/dl) 153 6 47 164 6 56 ns
HDL (mg/dl) 44 6 13 39 6 12 ns
Triglycerides (mg/dl) 237 6 128 221 6 127 ns
Change in lipid values
D Total cholesterol (mg/dl) 40 6 54 89 6 59 0.04
D Triglycerides (mg/dl) 47 6 114 105 6 98 ns
D LDL (mg/dl) 1 6 24 60 6 49 0.01
D HDL (mg/dl) 15 6 10 13 6 13 ns
BMI 5 body mass index; HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; ns 5 not significant.
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and without severe de novo lesions and in patients with and
without progression of donor lesions, respectively.
RESULTS
Patient demographics. We studied 93 cardiac transplant
recipients (76% men) with a mean age of 51 6 11 years. The
mean donor age was 30 6 12 years. Ischemic cardiomyop-
athy was the underlying cause in 50 patients (54%).
A total of 616 sites in 185 arteries (two arteries per
patient) were imaged in 93 patients. Of the 93 transplant
recipients, 36 (39%) contained at least one site with donor-
transmitted atherosclerosis (Fig. 1). At one-year follow-up,
progression of donor lesions was observed in 15 of the 36
patients (42%). In the first year after transplantation, 42 of
93 patients (45%) developed at least one site with a new
lesion of allograft vasculopathy (Fig. 2). Of these 42
patients, 20 (48%) also had donor-transmitted atheroscle-
rosis lesions. Of the 93 patients, 35 (38%) had neither
donor-transmitted atherosclerosis nor allograft vasculopathy
at one-year examination.
Allograft vasculopathy. CONVENTIONAL ATHEROSCLERO-
SIS RISK FACTORS. The mean values for conventional CAD
risk factors in patients with and without allograft vasculopa-
thy are shown in Table 1. Recipient age, gender, BMI,
hypertension, smoking history, diabetes mellitus and pres-
ence of pretransplant coronary disease were not associated
with the development of allograft vasculopathy. Pretrans-
plant lipid values including total cholesterol, LDL and
HDL cholesterol and triglycerides were similar in the two
Figure 1. Identical site in the left anterior descending artery from a
baseline (A) and one-year follow-up (B) study. The lesion in the baseline
image is from atherosclerosis transmitted from donor with maximum
plaque thickness of 0.5 mm. The branch vessel (arrow) along with
angiographic landmarks help to identify the same site from the follow-up
study. This is an example of donor lesion progression where the maximum
plaque thickness is increased by 0.4 mm at follow-up study.
Figure 2. Identical site in the left circumflex artery from a baseline (A) and
one-year follow-up (B) study. There is no intimal thickening at baseline.
However, when the same site is identified using pericardium and a branch
vessel as a landmark, significant intimal thickening (0.6 mm) is identified
at the same site. This is an example of de novo lesion of transplant
vasculopathy.
Table 3. Conventional Atherosclerosis Risk Factors in Patients With and Without Donor
Disease Progression
Characteristics
Donor Disease
p Value
No
Progression
(n 5 21)
Progression
(n 5 15)
Donor age (yr) 35.7 6 13.4 36.1 6 8.3 ns
Recipient age 51.9 6 10.8 56.7 6 5.6 0.12
Recipient gender (male %) 76 80 ns
Recipient hypertension (%) 33 13 ns
Smoking history (%) 61 62 ns
Diabetes (%) 5 33 0.06
BMI (kg/m2)
At the time of transplant 23.3 6 2.9 27.3 6 5.3 0.01
At 1-yr follow-up 26.1 6 3.8 29.3 6 7.1 ns
Pretransplant lipids
Total cholesterol (mg/dl) 183 6 51 193 6 48 ns
LDL (mg/dl) 125 6 42 129 6 41 ns
HDL (mg/dl) 33 6 9 32 6 10 ns
Triglycerides (mg/dl) 124 6 77 149 6 58 ns
Post-transplant lipids
Total cholesterol (mg/dl) 233 6 70 256 6 52 ns
LDL (mg/dl) 160 6 59 152 6 42 ns
HDL (mg/dl) 46 6 8 39 6 17 0.10
Triglycerides (mg/dl) 160 6 78 303 6 177 0.003
History of ischemic cardiomyopathy (%) 38 53 ns
BMI 5 body mass index; HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; ns 5 not significant.
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groups. Although the lipid profile at one year was signifi-
cantly different from baseline values, there were no differ-
ences between mean values for the subgroups with and
without newly acquired disease. The absolute change in
lipid values from baseline to one year was similar in patients
with and without allograft vasculopathy lesions.
The mean area stenosis in patients with allograft vascu-
lopathy ranged from 10% to 53% (median of 29%). The
changes in lipid values from baseline to one year were
significantly different in patients with .29% and #29% area
stenosis. Paradoxically, a trend toward higher pretransplant
total cholesterol and LDL cholesterol was observed in the
group with ,29% area stenosis, both p 5 0.06. Similarly, a
trend toward lower HDL cholesterol (p 5 0.09) was
observed in patients with mild vasculopathy lesions com-
pared with those with more severe lesions. However, by one
year there were no longer any differences in lipid values
comparing the subgroups with mild and more severe de
novo disease (Table 2). Therefore, the change in lipid values
exhibited a strong trend toward greater increases in the
group with more severe vasculopathy disease. In patients
with $29% area stenosis, univariate analysis showed signif-
icantly greater increase in total cholesterol (89 mg/dl vs.
40 mg/dl, p 5 0.02) and LDL cholesterol (60 mg/dl vs.
1 mg/dl, p 5 0.01). Linear regression analysis revealed a
moderate correlation between the increase in total and LDL
cholesterol and the severity of new lesions. However,
difference in the increase in triglycerides and HDL were not
significantly different comparing the subgroups with mild
and more severe allograft vasculopathy (Table 2). In a
multivariate analysis the change in LDL cholesterol was the
only predictor of severe transplant vasculopathy (p 5 0.02).
In the groups with and without allograft vasculopathy,
calcium channel blocker and statin therapy was adminis-
tered to similar proportions of patients (64% vs. 58%, p 5
0.5 and 19% vs. 12%, p 5 0.4, respectively).
IMMUNOLOGIC RISK FACTORS. Comparing subgroups with
and without allograft vasculopathy, there were no significant
differences in the number of patients with mismatches for
HLA, ABO, Rh and gender. Similarly, the number of
immunologic mismatches was similar in patients with mild
versus severe vasculopathy lesions. The number of rejection
episodes requiring treatment was similar in patients with
and without allograft vasculopathy (2.4 6 2.0, n 5 42;
2.7 6 1.8, n 5 49; p 5 0.42). Patients with more severe
allograft vasculopathy did not have more rejection episodes
(2.1 6 1.8 vs. 2.8 6 2.2; p 5 0.30).
DONOR-TRANSMITTED ATHEROSCLEROSIS. Because of in-
adequate information regarding donor characteristics, a full
profile of coronary risk factors in the donor was not
available. This limited the statistical power in determining
the risk factors associated with donor-transmitted athero-
sclerosis. However, donor age was available for all donors,
and by univariate analysis was predictive of the presence of
donor-transmitted atherosclerosis, p , 0.001. The donor
age was 26 6 11 years in the hearts without atherosclerosis
compared with 36 6 11 years for the hearts with athero-
sclerosis. There were no differences in gender, history of
hypertension, family history of CAD or smoking history
between the groups.
Progression of donor atherosclerosis lesions. CONVEN-
TIONAL ATHEROSCLEROSIS RISK FACTORS. Conventional
atherosclerosis risk factors in patients with and without
progression of donor disease are shown in Table 3. Al-
though information regarding donor risk factors was lim-
ited, the pretransplant recipient lipid profile was available in
68 patients and a post-transplant profile was available in all
patients. By univariate analysis BMI, but no other pretrans-
plant variable, was associated with progression of donor
lesions, p 5 0.01. Univariate analysis of post-transplant
variables demonstrated that patients with progression of
donor-transmitted lesions had a significantly higher serum
triglyceride level, 330 mg/dl versus 150 mg/dl, p 5 0.003. A
trend toward a higher prevalence of diabetes mellitus was
observed in patients with progression of donor lesions, p 5
0.06. Although donor age was a strong predictor of baseline
lesions, donor age was not a significant factor in predicting
which patients would have progression of these same
lesions. However, recipient age was slightly higher, 56
versus 51, in patients with progression of donor disease, but
this difference did not reach statistical significance, p 5
0.12. Although pretransplant BMI predicted progression of
donor lesions, the BMI at one year was not significantly
different in patients with and without progression. In a
multivariate analysis, serum triglyceride level and the pre-
transplant BMI were significant predictors for the progres-
sion of donor atherosclerosis, p 5 0.03.
In patients with and without donor atherosclerosis pro-
gression, calcium channel blocker and statin therapy was
administered to similar proportions of patients (71% vs.
47%, p 5 0.2, and 14% vs. 20%, p 5 0.7, respectively).
IMMUNOLOGIC RISK FACTORS. Mismatches in HLA,
ABO, Rh and gender were not significantly different in
patients with and without donor atherosclerosis progression.
Rejection episodes were similar in patients with and without
progression of donor lesions (2.1 6 1.8, n 5 15; 1.8 6 1.5,
n 5 21; p 5 0.62). There was no correlation between the
change in total cholesterol level and dose of cyclosporine
(r 5 0.17, p 5 0.2) or corticosteroid (r 5 20.008, p 5
0.95). Similarly, there was no correlation between the
change in LDL cholesterol and dose of cyclosporine (r 5
0.23, p 5 0.12) or corticosteroid (r 5 0.05, p 5 0.71).
DISCUSSION
Although most cardiac transplantation recipients die from
CAD, little is known about the factors responsible for rapid
progression in some patients and a more benign course in
others. The current study represents the first serial IVUS
investigation describing the influence of various risk factors
on the development and progression of the two distinct
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processes of transplant coronary disease: de novo vasculopa-
thy and donor atherosclerosis. Baseline imaging shortly after
transplantation along with careful site matching at one-year
examination led to identification of donor lesions and
assessment of any acquired allograft vasculopathy.
Allograft vasculopathy. Analysis of images at baseline and
one year demonstrates that conventional atherosclerosis risk
factors do not predict the development of lesions of allograft
vasculopathy in this population. Although high cholesterol
values did not predict allograft vasculopathy, a larger in-
crease in total and/or LDL cholesterol during the first year
after transplant was associated with development of more
severe vasculopathy lesions. Thus, the change in the cho-
lesterol level, but not the absolute values, influenced the
severity of allograft vasculopathy. Patients with lower total
and LDL cholesterol before transplantation, who had a
marked increase during the first year, were more likely to
have severe vasculopathy lesions compared with others.
Even though patients with mild disease and those with
more severe disease had similar cholesterol values at one
year, the magnitude of change in total and LDL cholesterol
during the first year after transplantation determined the
severity of those lesions. In a multivariate analysis of all lipid
levels, only the change in LDL cholesterol was an indepen-
dent predictor of vasculopathy lesion severity at one year.
Perhaps “normal” level varies individually and atherogene-
city increases when the respective normal levels are trans-
gressed.
The initial report by Kobashigawa et al. (6) demonstrated
significant benefit from pravastatin therapy in cardiac trans-
plant recipients. The pravastatin group had lower total
cholesterol levels than the control group and had better
survival. Further, in a subgroup of patients, intracoronary
ultrasound measurements at baseline and one year after
transplantation showed less progression in maximal intimal
thickness with pravastatin treatment. Two other investiga-
tions have confirmed the survival benefit of cholesterol
lowering in transplant recipients (7,8). Our study under-
scores the importance of change in lipid values on progres-
sion of transplant vasculopathy. From this study it can be
hypothesized that cardiac transplant patients may benefit
from therapy to minimize the elevation in their pretrans-
plant total and LDL cholesterol values, irrespective of the
absolute values.
Donor-transmitted atherosclerotic lesions. Previous
studies from our laboratory and others have demonstrated a
high prevalence of donor-transmitted disease in a contem-
porary transplant population (3,9). These studies have
confirmed that donor age is the most important determinant
of presence and severity of transmitted atherosclerosis in
transplant recipients. Although the relationship between
conventional risk factors and development of atherosclerosis
in children and young adults have been well documented,
limited data exist regarding the impact of these risk factors
on progression of donor-transmitted disease after transplan-
tation (10,11).
In our cohort of patients, approximately 40% had evi-
dence of at least one donor-transmitted lesion. In those
patients with donor-transmitted disease, progression oc-
curred in fewer than 50% of patients at one year. This
increase in severity may represent a form of allograft
vasculopathy rather than progression of conventional ath-
erosclerosis, although this process is not associated with
development of vasculopathy lesions at completely normal
sites. The magnitude of progression of donor disease was
limited; no patient developed an ischemia-producing lesion
or suffered a myocardial infarction. By univariate analysis,
donor lesions are more likely to progress during the first year
in patients who have hypertriglyceridemia, larger BMI at
transplantation and diabetes mellitus. Interestingly, recipi-
ent age but not donor age appeared to be more important
for the progression of donor lesions. This suggests that a
young heart behaves like an older heart when transplanted
in an “older milieu.” However, using multivariate analysis,
only pretransplant BMI and an elevated post-transplant
serum triglyceride level were significant factors influencing
the progression of donor-transmitted lesions.
The influence of triglyceride levels on development of
conventional atherosclerosis remains controversial, and its
role as an independent risk factor has been a source of
debate for many years (12–15). In the studies using angio-
graphic endpoints, but not clinical events, to assess the
progression of atherosclerosis, serum triglyceride is fre-
quently found to be a significant risk factor (16–20).
Similarly, hypertriglyceridemia has been associated with the
presence of transplant CAD as detected by angiographic or
intravascular ultrasound (21–25). However, in these prior
studies, distinction between donor-transmitted atheroscle-
rosis and de novo lesions of transplant vasculopathy was not
possible because of lack of an early baseline ultrasound study
with serial follow-up. We can now confirm that the asso-
ciation of triglyceride with transplant coronary disease
originates from progression of donor-transmitted lesions,
not accelerated development of de novo disease. Similarly,
the impact of BMI on transplant CAD was mainly on
pre-existing atherosclerotic plaque.
Immunologic factors. With respect to de novo lesions of
allograft vasculopathy, various immunologic factors have
been implicated in the pathogenesis. In our study, we did
not find an association between early (one year) allograft
vasculopathy and HLA mismatches or rejection episodes. It
remains possible that a longer follow-up in a larger number
of patients would have shown a significant effect. However,
the absence of any trend toward significance in our study
suggests that mismatches or rejection episodes do not
constitute a key factor in development of allograft vascu-
lopathy lesions at one year. Cytomegalovirus infection has
also been implicated in transplant CAD (26–28). In our
study population, cytomegalovirus infection was not com-
mon (6 out of 93 patients), and hence it was not possible to
investigate its role in this disease process.
This investigation is distinct from previous studies in
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three ways: intravascular ultrasound, not angiography, was
used to assess atherosclerosis; all patients had early baseline
IVUS imaging and efforts were made to image all three
epicardial coronaries (21,29–36). In addition, efforts were
undertaken to image large number of coronary artery seg-
ments, including more distal segments (37–41). This study
demonstrates the role of serial IVUS examination to distin-
guish donor-transmitted disease from allograft vasculopa-
thy. These two disease processes appear to have different
natural histories and risk factors. We have shown previously
that there is no interaction between prevalence of donor
atherosclerosis and subsequent development of allograft
vasculopathy (42). Similarly, the increase in plaque thick-
ness of donor atherosclerosis is independent of the
development of vasculopathy lesions within the same
coronary segment or the same patient. These findings
demonstrate that progression of donor lesions is deter-
mined by factors distinct from those affecting the devel-
opment of allograft vasculopathy. Nonetheless, both
these disease processes can occur in the same patient.
Thus, any intervention to alter the course of transplant
coronary disease must employ serial ultrasound imaging
to determine which, if any, of the two components is
affected by the therapy.
Study limitations. Although, by most standards, this was a
large serial IVUS study, all transplant investigations are
limited to a relatively small number of patients. Further-
more, although transplant coronary disease is an accelerated
process, one year still is a relatively short time to study the
natural history of atherosclerosis. However, even in this
short time frame, we observed a statistically significant
impact of lipid changes on the two disease processes. There
remains some doubt whether pretransplant lipid levels are
an accurate reflection of the “normal” metabolic state of
these patients. It is well known that there is a reduction in
cholesterol levels with advanced heart failure. Therefore,
pretransplant lipid levels may be lower than “healthy”
normal levels in the same patients. Pretransplant lipid data
were not obtainable in about one-fourth of the patients.
This limited our ability to determine the impact of change
in lipid values in these patients. Further, in this retrospec-
tive study, we did not have multiple lipid values for each
patient at predetermined time intervals (e.g., every three
months). This is also an important limitation considering
the dynamic changes in lipid values during the first year
following transplantation. Intravascular ultrasound assess-
ment of the transplant CAD also deserves some criticism.
We have selected the best and the worst site in a patient
from each segment for analysis. Because the IVUS pullbacks
were performed manually, volumetric analysis was not
feasible. This site analysis may not accurately reflect the
disease process in the entire coronary tree. Multivessel
imaging including distal vessels was used to minimize this
concern.
Conclusions. These findings have important implications
for post-transplant management. It has been proposed that
allograft vasculopathy is entirely an immunologically medi-
ated phenomenon (43–45). Accordingly, it has been as-
sumed that better immunosuppression alone would limit the
rate of progression of acquired allograft vasculopathy. The
current study supports the potential for an additional
strategy of aggressive control of LDL cholesterol and
provides an explanation for the benefit observed in clinical
investigation (7,8,46,47). Moreover, the goals of therapy in
transplant patients are not well defined. Until such infor-
mation is available, we recommend maintenance of lipid
values as close as possible to pretransplant values. Further,
serum triglyceride levels can be regulated to potentially slow
the progression of donor-transmitted atherosclerosis. Be-
cause recipient, but not donor, age influences progression of
donor atherosclerosis, it may be safe to liberalize donor age
limits to increase the availability of donor hearts (48).
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